Skip to main content
Heliyon logoLink to Heliyon
. 2023 Jun 19;9(6):e17361. doi: 10.1016/j.heliyon.2023.e17361

Mitochondrial citrate accumulation triggers senescence of alveolar epithelial cells contributing to pulmonary fibrosis in mice

Jie-Ru Hong a,1, Ling Jin a,1, Chen-Yu Zhang a, Wen-Jing Zhong a, Hui-Hui Yang a, Guan-Ming Wang a, Sheng-Chao Ma b,c, Cha-Xiang Guan a, Qing Li d,∗∗, Yong Zhou a,
PMCID: PMC10320039  PMID: 37416635

Abstract

Alveolar epithelial cell (AEC) senescence is implicated in the pathogenesis of pulmonary fibrosis (PF). However, the exact mechanism underlying AEC senescence during PF remains poorly understood. Here, we reported an unrecognized mechanism for AEC senescence during PF. We found that, in bleomycin (BLM)-induced PF mice, the expressions of isocitrate dehydrogenase 3α (Idh3α) and citrate carrier (CIC) were significantly down-regulated in the lungs, which could result in mitochondria citrate (citratemt) accumulation in our previous study. Notably, the down-regulation of Idh3α and CIC was related to senescence. The mice with AECs-specific Idh3α and CIC deficiency by adenoviral vector exhibited spontaneous PF and senescence in the lungs. In vitro, co-inhibition of Idh3α and CIC with shRNA or inhibitors triggered the senescence of AECs, indicating that accumulated citratemt triggers AEC senescence. Mechanistically, citratemt accumulation impaired the mitochondrial biogenesis of AECs. In addition, the senescence-associated secretory phenotype from senescent AECs induced by citratemt accumulation activated the proliferation and transdifferentiation of NIH3T3 fibroblasts into myofibroblasts. In conclusion, we show that citratemt accumulation would be a novel target for protection against PF that involves senescence.

Keywords: Citratemt accumulation, Alveolar epithelial cell, Senescence, Pulmonary fibrosis, Mitochondrial biogenesis

1. Introduction

Pulmonary Fibrosis (PF), a persistent, progressive, and age-related interstitial lung illness of unknown causes [1], is marked by a steady increase in breathlessness, diffuse cellular infiltrates, restrictive lung dysfunction, and impaired gas exchange [2]. Unfortunately, there is no cure for PF yet. Only pirfenidone [3] and nintedanib [4] have been known to reduce the rate of lung function decline, but they are unable to restore the progression or decrease mortality [5]. Therefore, it is essential to explore the molecular components that give rise to the pathogenesis of PF.

As PF is most commonly seen in older men, with a median survival of only 3.8 years after diagnosis in those over 65 years old [6], age is the most significant risk factor for this condition [7]. Cellular senescence, a state of permanent cell growth arrest, is thought to play a role in the pathogenesis of PF [8]. In mice, removing senescent cells using senolytics, such as dasatinib and quercetin, has been shown to attenuate bleomycin-induced PF [8]. Senescence is characterized by epigenetic abnormalities, telomere damage, DNA damage, and mitochondrial dysfunction, all of which are present in PF [9]. At the cellular level, there is considerable overlap between senescence and PF pathology [10]. Recent research has suggested that accelerated or aggravated alveolar epithelial cell (AEC) senescence is a critical mechanism in the initiation and progression of PF [11]. Induction of senescence in AECs drives PF [12]. Consequently, targeting AEC senescence is an attractive approach for preventing and treating PF. However, the molecular mechanism that triggers AEC senescence during PF is not fully understood.

Recent years have seen a surge of interest in the role of glucose metabolic reprogramming in cell senescence [13]. Warburg effect, a well-documented form of glucose metabolism reprogramming in tumor tissue, is a prime example [14]. Metabolites and intermediates of glucose metabolic reprogramming, such as hexokinase 2 [15] and pyruvate [16], have been identified as key signaling molecules in the process of cellular senescence. Citrate is mainly synthesized in the mitochondria from pyruvate, a product of glucose metabolism. Isocitrate dehydrogenase 3 (IDH3) catalyzes the transformation of citrate into α-ketoglutaric acid [17]. Additionally, citrate is transported from the mitochondria to the cytoplasm by citrate carrier (CIC, encoded by Slc25a1) and then broken down into acetyl-CoA and oxalacetic acid by ATP-dependent ATP citrate lyase (ACLY) [17]. Citrate has been found to be a crucial signaling molecule in cellular senescence and related diseases [18,19]. It has been observed that citrate can induce disruption of lipid metabolism in tumor cells, leading to tumor cell senescence and growth inhibition [20]. Moreover, inhibition of IDH1 has been demonstrated to induce cell senescence and inhibit tumor cell proliferation in highly malignant ovarian cancer cells [21]. In addition, our previous research has revealed that mitochondrial citrate (citratemt) accumulation can worsen necroptosis of AECs and consequently aggravate acute lung injury (ALI) in mice [22]. However, the role of citratemt in the senescence of AECs and PF has yet to be explored.

The maintenance of mitochondrial equilibrium is closely related to managing cell senescence [23]. Mitochondria play critical roles in the generation of energy and the stability of metabolic processes within the cell [24]. The maintenance of mitochondrial quality control is achieved through the processes of mitochondrial biogenesis, the processes of mitochondrial dynamics (fusion and fission), and the process of mitophagy [25]. Mitochondrial biogenesis is the growth and division of mitochondria to expand their numbers, and this process is managed by distinct pathways like the mitochondrial biogenesis factors PPARγ coactivator-1α (PGC1α)/nuclear respiratory factor 1 (NRF1)/mitochondrial transcription factor A (TFAM) pathway [26]. AECs from PF are found to have inadequate mitochondrial biogenesis [27], which is thought to be the cause of their senescence [24]. However, the molecular mechanism behind this disruption of mitochondrial biogenesis remains unknown.

In this study, we initially observed that citratemt was accumulated in AECs exposed to BLM in vivo and in vitro. By co-inhibiting Idh3α and CIC with shRNA or inhibitors, citratemt accumulation and senescence were induced in murine AECs. The accumulated citratemt was found to impede mitochondrial biogenesis and induce senescence in AECs. The senescence-associated secretory phenotype (SASP) secreted from senescent AECs activated the proliferation and transdifferentiation of fibroblasts into myofibroblasts. These findings suggest that citratemt accumulation could be a potential target for protecting against PF by inducing senescence.

2. Materials and methods

2.1. Animals

All experiments involving animals were conducted in accordance with the regulations established by the National Institutes of Health. Adult male C57BL/6 J mice weighing 20 ± 2 g were procured from Hunan SJA Laboratory Animal Co., Ltd (Hunan, China). The animals were kept in a 12-dark/light cycle with unrestricted access to food and water [28].

2.2. Animal treatment

Mice were randomly divided into two groups for PF models: the control group (n = 10), which received an intratracheal injection of saline, and the BLM group (n = 10), which received an intratracheal injection of BLM (3 mg/kg, in 50 μL saline, Nippon Kayaku, Japan). On Day 21, all mice were euthanized, and the lungs were collected for further analysis.

Mice were randomly divided into two groups for the virus-silencing models: the Con-shRNA group (n = 6), which received an intratracheal injection of an empty adenoviral vector, and the SPC-Slc25a1-shRNA + SPC-Idh3α-shRNA group (n = 6), which received an intratracheal injection of Slc25a1 (1 × 108 PFU/20 g, Genechem, Shanghai, China) and Idh3α (1 × 108 PFU/20 g, Genechem) adenoviral knockdown vectors containing the AEC-specific promoter SPC. On Day 30, all mice were euthanized, and their lungs were harvested for further analysis. All procedures were conducted under anesthesia with an intraperitoneal injection of sodium pentobarbital (80 mg/kg).

2.3. Pulmonary histopathological analysis

10% formalin was used to fix the left lung tissue, which was then embedded in paraffin and cut into 5 μm thick sections. H&E staining was employed to observe the tissue morphology, while Masson and Sirius's red staining was used to evaluate the collagen deposition. The Ashcroft score was utilized for the semi-quantitative assessment of fibrotic changes.

2.4. Immunofluorescent staining

Lung tissue sections were deparaffinized, permeabilized with 0.01 M citrate buffer, and heated for antigen retrieval, then blocking endogenous peroxidase with 3% H2O2 at 37 °C for 10 min. The cell samples were washed with PBS thrice and fixed with 4% paraformaldehyde for 15 min. The sections or cells were blocked with 5% bovine serum albumin (BSA, Biofroxx, Guangzhou, China) for 1 h and then incubated with primary antibodies in 1% BSA at 4 °C overnight. The sections were washed thrice with PBST and incubated with secondary antibodies for 1 h at room temperature. After washing in PBST three times, the nuclei were counterstained with DAPI (Solarbio, Beijing, China) for 30 s. The fluorescence was detected by a fluorescence microscope (Nikon, Japan). All antibodies used in the study are listed in Table 1.

Table 1.

Antibody dilutions and sources used in Western blot and Immunofluorescence in this study.

Antibodies Dilution ratio Source
Primary antibodies for western blotting
Rabbit-anti-IDH3α antibody 1:1500 Abcam
Rabbit-anti-CIC antibody 1:1500 Invitrogen
Rabbit-anti-p53 antibody 1:1500 Proteintech
Rabbit-anti-p21 antibody 1:1500 ABclonal
Rabbit-anti-γ-H2AX antibody 1:1500 Boster
Rabbit-anti-Collagen I antibody 1:1500 ABclonal
Rabbit-anti-α-SMA antibody 1:3000 SAB
Mouse-anti-PGC1α antibody 1:1500 Proteintech
Rabbit-anti-NRF1 antibody 1:1500 Proteintech
Rabbit-anti-TFAM antibody 1:1500 Proteintech
Rabbit-anti-Tom20 antibody 1:1500 Proteintech
Rabbit-anti-PCNA antibody 1:1500 Proteintech
Rabbit-anti-α-Tubulin antibody 1:10,000 Servicebio
Rabbit-anti-β-Tubulin antibody 1:5000 Servicebio
Secondary antibodies for western blotting
Goat anti-Rabbit antibody 1:7500 SAB
Goat anti-mouse antibody 1:5000 SAB
Primary antibodies for Immunofluorescence
Rabbit anti-surfactant protein C antibody 1:400 ABclonal
Mouse anti-p53 antibody 1:200 Abcam
Mouse anti-p21 antibody 1:400 Proteintech
Rabbit anti-IDH3α antibody 1:400 Abcam
Rabbit anti-CIC antibody 1:400 Invitrogen
Rabbit anti-Tom20 antibody 1:200 Proteintech
Mouse anti-E-cadherin antibody 1:250 Arigo
Rabbit anti-Collagen I/COL1A2 antibody 1:400 ABclonal
Rabbit anti-PCNA antibody 1:200 Proteintech
Secondary antibodies for Immunofluorescence
Green-fluorescent FITC goat anti-rabbit IgG 1:500 ABclonal
Red-fluorescent TRITC goat anti-rabbit IgG 1:500 ABclonal
Green-fluorescent FITC goat anti-mouse IgG 1:500 ABclonal
Red-fluorescent TRITC goat anti-mouse IgG 1:500 ABclonal

2.5. Cell culture

MLE12, a murine AEC cell line, was procured from the American Type Culture Collection (ATCC) and maintained in a humidified incubator at 37 °C and 5% CO2 in DMEM/F12 medium (Gibco, USA) supplemented with 2% newborn calf serum (BCS, Gibco) [29]. The NIH3T3 murine fibroblast cell lines were procured from ATCC. These cells were cultured in DMEM medium (Gibco) with 10% newborn calf serum at 37 °C and 5% CO2 [30].

2.6. Cell treatment

For AEC senescence models, two groups of MLE12 cells were established: the control and the BLM groups. Cells in the BLM group were exposed to 0.1 U/mL BLM (Aladdin, Shanghai, China) for 48 h. For the inhibitor models, MLE12 cells were planted into plates, then grouped into four groups: the control group, the CIC inhibitor group: cells were treated with 2 mM BTA (a CIC inhibitor, Sigma-Aldrich), the IDH3α inhibitor group: cells were treated with 100 μM TBT (IDH3 inhibitor, Aladdin), the CIC inhibitor + IDH3α inhibitor group: cells were treated with 2 mM CIC inhibitor and 100 μM IDH3α inhibitor. After 24 h, the cells were collected.

For the virus-silencing models, MLE12 cells were planted and grouped into two groups: the Con-shRNA group: cells were treated with empty vector virus, and the Slc25a1-shRNA + Idh3α-shRNA group: cells were infected with Slc25a1-shRNA lentivirus (multiplicity of infection:100, Genechem) and Idh3α-shRNA lentivirus (multiplicity of infection: 100, Genechem). After 16 h of lentivirus treatment, the supernatant was removed and replaced with a complete medium for 80 h. When MLE12 cells were cultured for 96 h, the supernatants containing SASP were collected as the conditioned medium (CM). The supernatant was centrifuged at 3000 rpm for 5 min, and the sediment was retained. NIH3T3 cells were planted into plates and treated with 10% supernatants containing SASP for 24 h.

2.7. Real-time quantitative polymerase chain reaction (RT-qPCR)

RT-qPCR was performed as in our previous study [31]. Total RNA was extracted from MLE12 or homogenized lung tissues using RNAiso Plus (Takara, Kusatsu, Japan). The concentration and quality of total RNA were evaluated by spectrophotometry (Thermo Fisher Scientific, USA). Total RNA was reverse-transcribed to cDNA utilizing a Reverse Transcription kit (Takara). Subsequently, RT-qPCR was carried out with TB Green PCR Master Mix (Takara) on a Bio-Rad real-time PCR system (CFX96 Touch™, Bio-Rad, USA). The mRNA levels were normalized in comparison to β-actin or 18S. The fold change for each mRNA was calculated using the 2−ΔΔCt method. All primer sequences are shown in Table 2.

Table 2.

Sequences of the primer used in this study.

Gene Forward 5′ to 3′ Reverse 5′ to 3′
m-Collagen I GAGCGGAGAGTACTGGATCG GCTTCTTTTCCTTGGGGTTC
m-Collagen III GCACAGCAGTCCAACGTAGA TCTCCAAATGGGATCTCTGG
m-p16 CTCTGCTCTTGGGATTGGC GTGCGATATTTGCGTTCCG
m-p21 GTGAGGAGGAGCATGAATGGA GAACAGGTCGGACATCACCA
m-p53 GCCCATGCTACAGAGGAGTC AAGGCTTGGAAGGCTCTAGG
m-Idh3α TTGCTGGTGGTGTTCAGACA ATTGCTGTGACATTGCGCTC
m-Slc25a1 TGCAGCCAGTGTCTTTGGAA AGGATCTTCAAGCCGCAGTC
m-Tgf-β1 ACTGGAGTTGTACGGCAGTG GGGGCTGATCCCGTTGATTT
m-Il-6 TCCGGAGAGGAGACTTCACA GTGACTCCAGCTTATCTCTTGGT
m-Il-8 TGCATGGACAGTCATCCACC ATGACAGACCACAGAACGGC
m-Il-1β CAGGCAGGCAGTATCACTCA AGCTCATATGGGTCCGACAG
m-Mmp2 TCGCCCATCATCAAGTTCCC CCTTGGGGCAGCCATAGAAA
m-18s AAACGGCTACCACATCCAAG CCTCCAATGGATCCTCGTTA
m-β-actin TTCCAGCCTTCCTTCTTG GGAGCCAGAGCAGTAATC

2.8. Western blotting

MLE12, NIH3T3, and lung tissue lysates were prepared using a RIPA Lysis Buffer (Solarbio) that included a protease inhibitor, phenylmethanesulfonyl fluoride (PMSF, Solarbio), and a phosphatase inhibitor Cocktail (CWBIO, Jiangsu, China). The protein concentration was then determined using the BCA Protein Assay Kit (Thermo Fisher Scientific). 30 μg of total protein was separated on a 12% SDS-PAGE gel and then transferred onto a polyvinylidene difluoride (PVDF) membrane. The membranes were initially blocked with 5% non-fat milk or BSA at room temperature for 1 h and then probed with primary antibodies overnight at 4 °C. Following this, the membranes were washed four times with TBST and incubated with HRP-conjugated secondary antibodies for 1 h at room temperature. Subsequently, protein signals were detected using an ECL kit (CWBIO) and ChemiDoc XRS (Bio-Rad). The quantitative results of the Western blot were determined by Image Lab Analyzer software (Bio-Rad). The antibodies used in the study are detailed in Table 1.

2.9. Measurement of mitochondrial membrane potential (MMP)

Measurement of MMP was accomplished following the previously established protocol [32]. The JC-1 Assay Kit (Beyotime, Shanghai, China) was employed to measure the MMP of cells. After washing twice with PBS, the cells cultured in 48-well plates were incubated with JC-1 for 20 min at 37 °C in the dark. In healthy mitochondria, JC-1 aggregates to form a polymer in the mitochondrial matrix, emitting intense red fluorescence (Excitation, 585 nm; Emission, 590 nm). Conversely, in unhealthy mitochondria, due to the decline/loss of MMP, JC-1 monomers are present in the cytoplasm, resulting in green fluorescence (Excitation, 514 nm; Emission, 529 nm). Consequently, alterations in the ratio of red/green indicate a change in MMP.

2.10. Detection of intracellular ROS and mitochondrial ROS generation

DCFH-DA (Beyotime, Shanghai, China) and MitoSOX Red (MCE, USA) were used to measure the production of intracellular reactive oxygen species (ROS) and mitochondrial ROS. After treatment, MLE12 cells were incubated at 37 °C for 25 min with DCFH-DA (10 μM) or MitoSOX Red (500 nM) and washed with PBS three times. The cells were observed by fluorescence microscopy (Nikon, Japan).

2.11. MitoTracker staining assay

MLE12 cells were stained with MitoTracker Green (Yeasen Biotech, 40742ES50) according to the manufacturer's instructions. Images were obtained using fluorescence microscopy (Nikon, Japan).

2.12. Senescence-associated β-galactosidase (SA-β-gal) staining

SA-β-gal staining was performed as previously described [10]. The MLE12 cells on a dish were stained using the Senescence β-Galactosidase Staining Kit (Beyotime) as the manufacturer's instructions. Firstly, the live cells were washed twice with PBS and then fixed with 1x Fixation solution for 15 min at room temperature. Subsequently, they were rinsed twice with PBS and stained with β-Galactosidase Staining Solution for 2 h overnight at 37 °C in a dry incubator (no CO2). The following day, the cell samples were observed, and pictures were captured using a microscope.

2.13. Cell growth assay

The cell growth assay was conducted following the previously established methodology [30]. Cell Counting Kit-8 (CCK-8, Dojindo Molecular Technologies, Japan) was used to assess cell viability. Cells were seeded into 96-well plates (1000 cells/well) and then, after 12 h of serum deprivation, were exposed to various concentrations of CM containing SASP for 24 h. Subsequently, 10 μL of CCK-8 was added to each well, and the plates were incubated at 37 °C for an additional 1 h. The absorbance was then measured at 450 nm using a UV spectrophotometer (Thermo Fisher Scientific).

2.14. Statistical analysis

Data were presented as mean ± SD and obtained from at least three independent experiments. Statistical analysis was conducted using GraphPad Prism 9 software (GraphPad Software, Inc., San Diego, CA, USA) or SPSS 26.0 (IBM). To determine the differences between the two groups, an unpaired two-tailed t-test was conducted. Correlations were then calculated using Spearman rank-order coefficients. Statistical comparisons among the multiple groups were assessed with ANOVA, and Tukey's test was used as a post hoc test for pairwise comparisons. The results were expressed as mean ± SD values and statistical significance was set at P < 0.05.

3. Results

3.1. Accumulation of citratemt occurs in the lungs of PF

Citratemt participates in the TCA cycle through the downstream key enzymes IDH3 and succinate dehydrogenase. And citratemt can be transported into the cytoplasm via CIC (Fig. 1A) [33]. First, microarray analysis of GSE185691 revealed a reduction in the IDH3α and SLC25A1 mRNA levels in the lungs of IPF patients compared to those of healthy controls (Fig. 1B and C). Next, we investigated the change of CIC and IDH3α in the PF lung tissue. Compared with the control group, the mice in the PF group showed infiltration of inflammatory cells, thickening of alveolar septa, and fibrous scar (Fig. 1D). The expression of Col3a1 mRNA was up-regulated in the lungs of BLM-induced PF mice (Fig. 1E). These were consistent with previously published findings [34]. Further, we detected the mRNA and protein expression of IDH3α and CIC in the lungs. We found that the expressions of IDH3α and CIC in the lungs were down-regulated under the BLM challenge (Fig. 1F–J). Collectively, these data indicate that citratemt accumulation occurs in the lungs of PF.

Fig. 1.

Fig. 1

IDH3α and CIC expression are down-regulated in the lungs of PF. (A) The pathway of citrate metabolism and transportation. (B–C) Human IDH3α and SLC25A1 mRNA expression in the lung tissues from IPF subjects (n = 4) and controls (n = 7) were determined by microarray (GSE185691). C57BL/6 J mice received BLM (3 mg/kg, intratracheal injection) to establish a PF model. Mice were sacrificed on the 21st day after the BLM injection. (D) Lung histopathology was stained with Masson's trichrome (bar = 100 μm). (E) RT-qPCR results showed increased Col3a1 mRNA on the 21st day after BLM administration (n = 6–10). (F–G) RT-qPCR results showed decreased Idh3α and Slc25a1 mRNA expressions on the 21st day after BLM administration (n = 6–10). (H–J) Western blot showed decreased IDH3α and CIC proteins on the 21st day after BLM administration (n = 6). Data are expressed as the mean ± SD. *P < 0.05.

3.2. Citratemt accumulation is positively related to lung aging

Next, we investigated the role of citratemt accumulation in PF. The mRNA expressions of senescence-related molecules p16, p21, and p53 were significantly increased (Fig. 2A–C). We also found that the protein expressions of p53 and γ-H2AX were significantly up-regulated in the lungs of PF mice (Fig. 2D–F). Immunofluorescent staining showed that the increased fluorescence intensity of p53 overlapped with surfactant protein C (SPC) (Fig. 2I), indicating the senescence of AECs during PF. Interestingly , not only IDH3α protein expression negatively correlated with the p53 protein in the lungs of PF mice (Fig. 2G), but also CIC protein expression negatively correlated with the p53 protein (Fig. 2H). Aging is an essential feature in PF patients [1]. We found that the expressions of IDH3α and CIC protein were decreased in the lungs of old mice compared with young mice (Fig. 2J-L). IDH3α protein expression was negatively correlated with the p21 protein in the lung tissues of old mice (Fig. 2M). Altogether, these results demonstrate that citratemt accumulation is positively related to lung aging.

Fig. 2.

Fig. 2

Downregulation of IDH3α and CIC are positively related to lung aging. C57BL/6 J mice received BLM (3 mg/kg, intratracheal injection) to establish a PF model and were sacrificed on the 21st day after the BLM injection. (A–C) The mRNA expressions of p16, p21, and p53 were detected by RT-qPCR (n = 5–10). (D–F) The protein expressions of p53 and γ-H2AX were detected by Western Blot. (G–H) The correlations of p53 with IDH3α and CIC were analyzed by GraphPad Prism 9. (I) The fluorescence intensity of SPC and p53 was detected by immunofluorescence (bar = 20 μm), green: SPC, red: p53. (J–L) The protein expressions of IDH3α and CIC were detected by Western Blot. (M) The fluorescence intensity of IDH3α and p21 were detected by immunofluorescence (bar = 50 μm), green: IDH3α, red: p21. Data are expressed as the mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001.

3.3. AECs-specific citratemt accumulation leads to senescence and spontaneous fibrosis in the lungs

To further clarify the effect of citratemt accumulation in AECs during fibrosis and aging, we injected SPC promoter-adenovirus silencing vectors for Idh3α (Idh3α-shRNA) and Slc25a1 (Slc25a1-shRNA) (1 × 108 PFU/20 g) to establish AEC-specific citratemt accumulation mice model as our previous study [22]. Immunofluorescence staining showed co-localization of E-cadherin and IDH3α or CIC was decreased in AECs-specifically silencing Idh3α and Slc25a1 group, suggesting that AEC-specific citratemt accumulation occurred (Fig. S1). In pathological morphology, mice receiving AEC-specific Idh3α-shRNA and Slc25a1-shRNA treatment showed apparent inflammatory cell infiltration, alveolar wall thickness, and fiber foci formation in the lungs (Fig. 3A). Remarkably, silencing AECs-specific IDH3α and CIC increased lung fibrosis scores (Fig. 3B) and up-regulated the protein expression of collagenⅠ in the lungs (Fig. 3C and D). These results suggest that AECs-specific citratemt accumulation triggers spontaneous PF. Interestingly, we found that p53, p21, and γ-H2AX protein expressions were increased in the lungs of mice receiving AEC-specific Idh3α shRNA and Slc25a1 shRNA treatment (Fig. 3E–H). And senescence marker p21 was co-localized with SPC (Fig. 3I). Collectively, these data suggest that AECs-specific citratemt accumulation leads to senescence and spontaneous fibrosis in mice lungs.

Fig. 3.

Fig. 3

Silencing IDH3α and CIC leads to senescence and spontaneous fibrosis in the lungs. C57BL/6 J mice were intratracheally injected with SPC promoter-adenovirus silencing vectors for Idh3α and Slc25a1 (1 × 108 PFU/20 g) and survived to the 30th day. (A) Lung histopathology was performed with H&E (bar = 100 μm), Masson's trichrome (bar = 100 μm), and Sirius Red staining (bar = 50 μm) 30 days after the adenovirus injection. (B) The fibrosis score was evaluated independently by three blinded pathologists (n = 6). (C–D) The Collagen Ⅰ protein expression was detected by Western blot (n = 6). (E–H) The protein expressions of p53, p21, and γ-H2AX were detected by Western Blot (n = 6). (I) The fluorescence intensity of SPC and p21 were detected by immunofluorescence (bar = 50 μm), green: p21, red: SPC. Data are expressed as the mean ± SD. *P < 0.05 and **P < 0.01.

3.4. Citratemt accumulation drives senescence of AECs in vitro

Senescent AECs drive PF by exhausting the alveolar regenerative potential and triggering pathological remodeling [35]. To illustrate the role of citratemt accumulation in AECs senescence, we first investigated whether citratemt accumulation occurred in senescent AECs in vitro. Murine AECs MLE12 were treated with BLM (0.01 U/mL) for 48 h. We found that BLM up-regulated the p53 mRNA and protein expressions while down-regulated the IDH3α and CIC protein expressions (Fig. 4A–F). And the levels of IDH3α and CIC were negatively correlated with the p53 protein (Fig. 4G and H). Next, we established a citratemt accumulation model with Idh3α-shRNA and Slc25a1-shRNA (Fig. 4L − N), which could induce citratemt accumulation reported in our previous study [22]. We found that citratemt accumulation increased the intensity of SA-β-gal staining positive (Fig. 4O) and significantly elevated the expression of p53 and p21 (Fig. 4P-R). Citratemt accumulation also significantly decreased the level of proliferating cell nuclear antigen (PCNA) in MLE12 cells (Fig. S2). In addition, we pretreated MLE12 with IDH3 and CIC inhibitors (BTA and TBT). Compared with the control group, MLE12 cells receiving BTA and TBT exerted higher senescence-related protein levels (Fig. 4I-K). Overall, these data indicate that citratemt accumulation drives the senescence of AECs in vitro.

Fig. 4.

Fig. 4

Silencing IDH3α and CIC drives the senescence of AECs in vitro. MLE12 cells were treated with BLM (0.01 U/mL) for 48 h. (A–C) The p53 level was measured by RT-qPCR and Western Blot (n = 3). (D–F) The protein expressions of IDH3α and CIC were measured by Western Blot (n = 3). (G–H) The correlations of p53 with IDH3α and CIC were analyzed by GraphPad Prism 9. (I–K) MLE12 cells were treated with IDH3α inhibitor (100 μM) and CIC inhibitor (2 mM) for 24 h, and the levels of p53 and p21 proteins were detected by Western Blot (n = 3). MLE12 cells were treated with Idh3α-shRNA and Slc25a1-shRNA for 96 h. (L–N) The protein expressions of IDH3α and CIC were detected by Western Blot (n = 3). (O) Senescence was confirmed by SA-β-gal staining (bar = 50 μm). (P–R) The protein expressions of p53 and p21 were detected by Western Blot (n = 3). Data are expressed as the mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001.

3.5. Citratemt accumulation impairs the mitochondrial biogenesis of AECs

Mitochondrial dysfunction has been widely implicated in PF [27]. Mitochondrial membrane potential (MMP), an index of mitochondrial bioenergetics, was impaired in MLE12 cells with citratemt accumulation (Fig. 5A). Citratemt accumulation was also seen to significantly promote the creation of intracellular and mitochondrial ROS (Fig. 5B), indicating the mitochondrial dysfunction of AECs. Mitochondrial biogenesis plays a crucial role in producing new healthy mitochondria [25]. In vitro, we found that citratemt accumulation reduced the levels of mitochondrial biogenesis factors: TOM20, PGC1α, TFAM, and NRF1 in MLE12 cells (Fig. 5D–H). The mitochondrial number was much lower after citratemt accumulation than the control group (Fig. 5C). In vivo, citratemt accumulation also decreased the expressions of PGC1α and TFAM in mice lungs (Fig. 5I–K). These data suggest that citratemt accumulation damages the mitochondrial biogenesis of AECs, which may contribute to AEC senescence.

Fig. 5.

Fig. 5

Silencing IDH3α and CIC damages the mitochondrial biogenesis in AECs. MLE12 cells were treated with Idh3α-shRNA and Slc25a1-shRNA for 96 h. (A) Representative images of MLE12 cells loaded with the mitochondrial membrane potential indicator JC-1 (bar = 20 μm). (B) Intracellular ROS were measured by DCFH-DA staining and the mitochondrial ROS were determined by MitoSOX staining (bar = 100 μm). (C) MitoTracker Green staining and immunofluorescence of TOM20 determined the mitochondrial number (bar = 20 μm). (D–H) The levels of Tom20, PGC1α, TFAM, and NRF1 were detected by Western Blot (n = 3). C57BL/6 J mice were intratracheally injected with SPC promoter-adenovirus silencing vectors for Idh3α and Slc25a1 (1 × 108 PFU/20 g) and survived to the 30th day. (I–K) The protein expressions of TFAM and PGC1α were detected by Western Blot (n = 6). Data are expressed as the mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001.

3.6. Citratemt accumulation-triggered AECs senescence derives fibroblast proliferation and transdifferentiation via SASP

Senescent AECs release a considerable amount of SASP, such as transforming growth factors and cytokines, which stimulate the proliferation and transdifferentiation of neighboring lung fibroblasts, thus hastening the progression of PF [10,30]. To evaluate the effects of CM derived from AECs with citratemt accumulation on fibrosisin vitro, we employed an embryonic mouse fibroblast cell line (NIH3T3). MLE12 cells were treated with Slc25a1-shRNA and Idh3α-shRNA, and the cell culture supernatant was collected as CM (Fig. 6A and B). The CCK8 assay demonstrated that 10% CM had a marked effect on increasing cell viability in NIH3T3 cells compared to the control group (Fig. 6C). Besides, fibroblast activation markers (collagen I and α-SMA) were increased after exposure to 10% CM in NIH3T3 cells (Fig. 6D–F). Those findings indicate that citratemt accumulation triggers AECs senescence, thus inducing fibroblast proliferation and transdifferentiation via SASP.

Fig. 6.

Fig. 6

Silencing IDH3α and CIC triggers AECs senescence and induces fibroblast proliferation and transdifferentiation via SASP. MLE12 cells were treated with Idh3α-shRNA and Slc25a1-shRNA for 96 h. (A) The mRNA expressions of Tgf-β1, Il-6, Il-8,Il-1β and Mmp2 were detected by RT-qPCR (n = 3). (B) The protocol for conditioned medium experimentation. MLE12 cells were treated with Idh3α-shRNA and Slc25a1-shRNA for 96 h, and cell culture supernatant was collected as CM. Fibroblasts were starved (without serum) for 12 h and then treated with different concentrations of CM for 24 h. (C) CCK8 assay assessed the results of different groups at 5%, 10%, and 20% of CM on NIH3T3 cell viability (n = 3). (D–F) The protein expressions of collagen I and α-SMA were detected by Western Blot (n = 3). Data are expressed as the mean ± SD. *P < 0.05 and ***P < 0.001.

4. Discussion

In this study, we identified a novel role of citratemt accumulation in regulating the senescence of AECs and its potential mechanism on BLM-induced PF in vivo and in vitro. Mechanistically, citratemt accumulation impaired mitochondrial biogenesis, triggering senescence of AECs. Furthermore, SASP secreted by senescent AECs induced the proliferation and differentiation of lung fibroblasts, thus accelerating the process of PF (Fig. 7). Taken together, these data suggest that citratemt accumulation is involved in AEC senescence during PF.

Fig. 7.

Fig. 7

Schematic representation of the proposed mechanisms for citratemtaccumulation-induced AECs senescence during PF. Citratemt accumulation triggers AECs senescence during BLM-induced PF by impairing mitochondrial biogenesis.

Aging drives PF characterized by the mass secretion of profibrotic factors and lung parenchyma and interstitium destruction, leading to poor respiratory function and life quality [5,11]. Emerging evidence has revealed that the senescence of AECs drives PF through both consuming alveolar regeneration potential and SASP-induced pathological remodeling. Therefore, pharmacological manipulation of AECs’ senescence signaling is a reasonable therapeutic strategy for PF. Our previous studies have found that COX-2/sEH dual inhibitor PTUPB alleviates the BLM-induced PF by inhibiting AEC senescence [10]. Blocking triggering receptor expressed on myeloid cells-1, an inflammatory receptor, relieves AEC senescence, rescuing PF outcomes [11]. Herein, we identified citratemt accumulation as a senescent stimulus in PF.

Glucose metabolism is an indispensable life process, supplying cells and organisms with energy and materials [36,37]. Metabolic enzymes and their metabolites in the TCA cycle are related to aging [[38], [39], [40]]. For example, inhibition of IDH1 could induce ovarian cancer cell senescence and thus inhibit tumor cell growth [21]. Fumarate hydratase (FH) is a key enzyme in the TCA cycle, which can convert fumarate into malic acid. FH+/- rat primary fibroblasts exhibited anti-aging properties [41]. Pyruvate produced by glycolysis can be converted into citrate after entering the mitochondria, which participates in Krebs through IDH3. Alternatively, it can be transported to the cytoplasm via CIC on the mitochondrial surface to produce acetyl-CoA and oxaloacetate under the action of ACLY [42,43]. IDH3 and CIC are highly related to citratemt homeostasis. Decreased levels of IDH3 and CIC suggest an accumulation of citratemt [22]. Our prior investigation revealed that citratemt accumulation occurred and facilitated necroptosis of AECs in lipopolysaccharide-induced ALI mice [22]. Promisingly, we found that mice with AECs-specific Idh3α and Slc25a1 deficiency exhibited inflammatory cell infiltration, fiber foci formation, down-regulation of SPC, and up-regulation of aging-related proteins in the lungs of mice. Moreover, in vitro, AECs with citratemt accumulation showed senescent characteristics, with high expression of aging-related proteins and increased SA-β-gal activity. AECs are structural cells in the lungs, and injured AECs affect gas exchange, which is a significant reason for dyspnea in PF patients [44]. Various damage factors stimulate AECs and destroy the alveolar epithelial integrity, thus exacerbating PF. SPC is one of the specific markers of AECs, and its decrease can increase alveolar surface tension and aggravate AECs injury. Consequently, these data support that citratemt accumulation induces AEC injury via senescence.

Mitochondria act as a central hub in the mammalian cell. Its homeostasis and precise function are critical for cell fitness and survival [27]. The maintenance of mitochondrial mass is achieved via mitochondrial biogenesis, mitochondrial dynamics, and mitophagy [45]. Mitochondrial biogenesis is essential for regulating newborn mitochondria to guarantee cell energy metabolism [46]. It mainly involves the replication of mitochondrial DNA (mtDNA), the synthesis of mtDNA-encoded proteins, and the coordination of mitochondrial dynamics. PGC1α, as a major co-transcription factor, translocates to the nucleus and binds to NRF1/2, transcriptionally activating the expression of TFAM. This process drives mtDNA transcription and replication [47,48]. Mitochondrial biogenesis deficiency is an early marker of mitochondrial damage, which leads to decreased ATP synthesis and oxidative stress, and ultimately cell senescence [49]. For example, PGC1α deficiency reduces proliferation of vascular smooth muscle cells, while simultaneously increasing the level of ROS and senescence [50]. Here, our findings indicate that AECs with accumulated citratemt had reduced expression of Tom20, PGC1α, TFAM, and NRF1 proteins. In addition, accumulated citratemt increased ROS and mitochondrial ROS generation, as well as decreased MMP in AECs, which are key signs of mitochondrial dysfunction [32]. Moreover, mice with AECs-specific Idh3α and Slc25a1 deficiency showed down-regulated levels of TFAM and PGC1α. These results suggest that increased citratemt accumulation harms mitochondrial biogenesis and reduces MMP of AECs, thus intensifying the senescence of AECs.

Emerging evidence has demonstrated that senescent AECs can promote the proliferation and differentiation of lung fibroblasts through the secretion of growth factors and cytokines as part of the SASP, thus accelerating the process of PF [35]. In this study, we found that the conditioned medium from AECs with citratemt accumulation significantly stimulated fibroblast proliferation and activation. Collectively, we speculate that mitochondrial citratemt accumulation impairs mitochondrial function, triggering AEC senescence, thus exacerbating lung fibrosis. To some extent, our study also reveals a novel mechanism underlying the initiation of cellular senescence in AECs: citratemt accumulation.

The limitations of this study are: i) In addition to senescence, apoptosis and necroptosis of AECs are also important causes of AEC loss in PF. While it is still unclear whether apoptosis (or necroptosis) occurs upon citrate accumulation in AECs during PF. ii) Besides measuring CIC and Idh3α protein levels, the direct citrate content in BLM-induced AECs or the mice lungs has to be detected in future studies. iii) Our study suggested decreased mRNA levels of IDH3α and SLC25A1 in IPF patients compared to healthy. Further studies using clinical patient specimens will be necessary to demonstrate the clinical significance of the increased citrate in IPF pathogenesis.

In conclusion, this is the first report revealing that citratemt accumulation contributes to the senescence of AECs during PF by mediating mitochondrial dysfunction. Therefore, targeting citratemt accumulation could be a potential strategy to reduce AEC senescence in PF patients. Our findings indicate that citratemt accumulation is an intrinsic pathogenic mechanism of PF.

Author contribution statement

Jie-Ru Hong, Ling Jin: Performed the experiments; Wrote the paper.

Chen-Yu Zhang, Wen-Jing Zhong, Hui-Hui Yang: Performed the experiments.

Guan-Ming Wang: Analyzed and interpreted the data.

Sheng-Chao Ma, Cha-Xiang Guan: Contributed reagents, materials, analysis tools or data.

Qing Li, Yong Zhou: Conceived and designed the experiments; Contributed reagents, materials, analysis tools or data.

Funding statement

Cha-Xiang Guan was supported by National Natural Science Foundation of China {82170096}, Innovative Research Group Project of the National Natural Science Foundation of China {91949110}.

Qing Li was supported by Natural Science Foundation of Hunan Province {2020JJ4452}.

Jie-Ru Hong was supported by Fundamental Research Funds for Central Universities of the Central South University {2021zzts0916}.

Ling Jin was supported by Fundamental Research Funds for Central Universities of the Central South University {2021zzts0918}.

Data availability statement

Data will be made available on request.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Footnotes

Appendix A

Supplementary data to this article can be found online at https://doi.org/10.1016/j.heliyon.2023.e17361.

Contributor Information

Qing Li, Email: liqing2381669@163.com.

Yong Zhou, Email: zhouyong421@csu.edu.cn.

Abbreviations

ACLY

ATP-dependent ATP citrate lyase

AECs

alveolar epithelial cells

BLM

Bleomycin

CM

conditioned medium

CIC

citrate carrier

FH

fumarate hydratase

IDH3

isocitrate dehydrogenase 3

mtDNA

mitochondrial DNA

MMP

mitochondrial membrane potential

TFAM

mitochondrial transcription factor A

NRF1

nuclear respiratory factor 1

PF

pulmonary fibrosis

PGC1α

PPARγ coactivator-1α

PCNA

proliferating cell nuclear antigen

ROS

reactive oxygen species

SASP

senescence-associated secretory phenotype

SA-β-gal

senescence-associated β-galactosidase

SPC

surfactant protein C

TCA cycle

tricarboxylic acid cycle

Appendix A. Supplementary data

The following is the Supplementary data to this article.

Multimedia component 1
mmc1.pptx (22.6MB, pptx)

References

  • 1.Cho S.J., Stout-Delgado H.W. Aging and lung disease. Annu. Rev. Physiol. 2020;82:433–459. doi: 10.1146/annurev-physiol-021119-034610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Raghu G., Remy-Jardin M., Richeldi L., Thomson C.C., Inoue Y., Johkoh T., Kreuter M., Lynch D.A., Maher T.M., Martinez F.J., Molina-Molina M., Myers J.L., Nicholson A.G., Ryerson C.J., Strek M.E., Troy L.K., Wijsenbeek M., Mammen M.J., Hossain T., Bissell B.D., Herman D.D., Hon S.M., Kheir F., Khor Y.H., Macrea M., Antoniou K.M., Bouros D., Buendia-Roldan I., Caro F., Crestani B., Ho L., Morisset J., Olson A.L., Podolanczuk A., Poletti V., Selman M., Ewing T., Jones S., Knight S.L., Ghazipura M., Wilson K.C. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 2022;205:e18–e47. doi: 10.1164/rccm.202202-0399ST. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Behr J., Prasse A., Kreuter M., Johow J., Rabe K.F., Bonella F., Bonnet R., Grohe C., Held M., Wilkens H., Hammerl P., Koschel D., Blaas S., Wirtz H., Ficker J.H., Neumeister W., Schonfeld N., Claussen M., Kneidinger N., Frankenberger M., Hummler S., Kahn N., Tello S., Freise J., Welte T., Neuser P., Gunther A., investigators R. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir. Med. 2021;9:476–486. doi: 10.1016/S2213-2600(20)30554-3. [DOI] [PubMed] [Google Scholar]
  • 4.Umemura Y., Mitsuyama Y., Minami K., Nishida T., Watanabe A., Okada N., Yamakawa K., Nochioka K., Fujimi S. Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: an interventional study. Int. J. Infect. Dis. 2021;108:454–460. doi: 10.1016/j.ijid.2021.05.055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Spagnolo P., Kropski J.A., Jones M.G., Lee J.S., Rossi G., Karampitsakos T., Maher T.M., Tzouvelekis A., Ryerson C.J. Idiopathic pulmonary fibrosis: disease mechanisms and drug development. Pharmacol. Ther. 2021;222 doi: 10.1016/j.pharmthera.2020.107798. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.George P.M., Patterson C.M., Reed A.K., Thillai M. Lung transplantation for idiopathic pulmonary fibrosis. Lancet Respir. Med. 2019;7:271–282. doi: 10.1016/S2213-2600(18)30502-2. [DOI] [PubMed] [Google Scholar]
  • 7.Martinez F.J., Collard H.R., Pardo A., Raghu G., Richeldi L., Selman M., Swigris J.J., Taniguchi H., Wells A.U. Idiopathic pulmonary fibrosis. Nat. Rev. Dis. Prim. 2017;3 doi: 10.1038/nrdp.2017.74. [DOI] [PubMed] [Google Scholar]
  • 8.Schafer M.J., White T.A., Iijima K., Haak A.J., Ligresti G., Atkinson E.J., Oberg A.L., Birch J., Salmonowicz H., Zhu Y., Mazula D.L., Brooks R.W., Fuhrmann-Stroissnigg H., Pirtskhalava T., Prakash Y.S., Tchkonia T., Robbins P.D., Aubry M.C., Passos J.F., Kirkland J.L., Tschumperlin D.J., Kita H., LeBrasseur N.K. Cellular senescence mediates fibrotic pulmonary disease. Nat. Commun. 2017;8 doi: 10.1038/ncomms14532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Korfei M., MacKenzie B., Meiners S. The ageing lung under stress. Eur. Respir. Rev. 2020;29 doi: 10.1183/16000617.0126-2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Zhang C.Y., Duan J.X., Yang H.H., Sun C.C., Zhong W.J., Tao J.H., Guan X.X., Jiang H.L., Hammock B.D., Hwang S.H., Zhou Y., Guan C.X. COX-2/sEH dual inhibitor PTUPB alleviates bleomycin-induced pulmonary fibrosis in mice via inhibiting senescence. FEBS J. 2020;287:1666–1680. doi: 10.1111/febs.15105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Xiong J.B., Duan J.X., Jiang N., Zhang C.Y., Zhong W.J., Yang J.T., Liu Y.B., Su F., Zhou Y., Li D., Yang H.H., Guan C.X. TREM-1 exacerbates bleomycin-induced pulmonary fibrosis by aggravating alveolar epithelial cell senescence in mice. Int. Immunopharm. 2022;113 doi: 10.1016/j.intimp.2022.109339. [DOI] [PubMed] [Google Scholar]
  • 12.Yao C., Guan X., Carraro G., Parimon T., Liu X., Huang G., Mulay A., Soukiasian H.J., David G., Weigt S.S., Belperio J.A., Chen P., Jiang D., Noble P.W., Stripp B.R. Senescence of alveolar Type 2 cells drives progressive pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2021;203:707–717. doi: 10.1164/rccm.202004-1274OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wang Q., Duan L., Li X., Wang Y., Guo W., Guan F., Ma S. Glucose metabolism, neural cell senescence and alzheimer's disease. Int. J. Mol. Sci. 2022;23 doi: 10.3390/ijms23084351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Poff A., Koutnik A.P., Egan K.M., Sahebjam S., D'Agostino D., Kumar N.B. Targeting the Warburg effect for cancer treatment: ketogenic diets for management of glioma. Semin. Cancer Biol. 2019;56:135–148. doi: 10.1016/j.semcancer.2017.12.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Hariton F., Xue M., Rabbani N., Fowler M., Thornalley P.J. Sulforaphane delays fibroblast senescence by curbing cellular glucose uptake, increased glycolysis, and oxidative damage. Oxid. Med. Cell. Longev. 2018;2018 doi: 10.1155/2018/5642148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Olenchock B.A., Vander Heiden M.G. Pyruvate as a pivot point for oncogene-induced senescence. Cell. 2013;153:1429–1430. doi: 10.1016/j.cell.2013.06.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Strzyz P. Alternative cycle for citrate. Nat. Rev. Mol. Cell Biol. 2022;23:305. doi: 10.1038/s41580-022-00475-w. [DOI] [PubMed] [Google Scholar]
  • 18.Leandro J.G., Espindola-Netto J.M., Vianna M.C., Gomez L.S., DeMaria T.M., Marinho-Carvalho M.M., Zancan P., Paula Neto H.A., Sola-Penna M. Exogenous citrate impairs glucose tolerance and promotes visceral adipose tissue inflammation in mice. Br. J. Nutr. 2016;115:967–973. doi: 10.1017/S0007114516000027. [DOI] [PubMed] [Google Scholar]
  • 19.Fontana L., Mitchell S.E., Wang B., Tosti V., van Vliet T., Veronese N., Bertozzi B., Early D.S., Maissan P., Speakman J.R., Demaria M. The effects of graded caloric restriction: XII. Comparison of mouse to human impact on cellular senescence in the colon. Aging Cell. 2018;17 doi: 10.1111/acel.12746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Zhao Y., Liu X., Si F., Huang L., Gao A., Lin W., Hoft D.F., Shao Q., Peng G. Citrate promotes excessive lipid biosynthesis and senescence in tumor cells for tumor therapy. Adv. Sci. 2022;9 doi: 10.1002/advs.202101553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Dahl E.S., Buj R., Leon K.E., Newell J.M., Imamura Y., Bitler B.G., Snyder N.W., Aird K.M. Targeting IDH1 as a prosenescent therapy in high-grade serous ovarian cancer. Mol. Cancer Res. 2019;17:1710–1720. doi: 10.1158/1541-7786.MCR-18-1233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Yang H.H., Jiang H.L., Tao J.H., Zhang C.Y., Xiong J.B., Yang J.T., Liu Y.B., Zhong W.J., Guan X.X., Duan J.X., Zhang Y.F., Liu S.K., Jiang J.X., Zhou Y., Guan C.X. Mitochondrial citrate accumulation drives alveolar epithelial cell necroptosis in lipopolysaccharide-induced acute lung injury. Exp. Mol. Med. 2022;54:2077–2091. doi: 10.1038/s12276-022-00889-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Miwa S., Kashyap S., Chini E., von Zglinicki T. Mitochondrial dysfunction in cell senescence and aging. J. Clin. Invest. 2022;132 doi: 10.1172/JCI158447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Moss B.J., Ryter S.W., Rosas I.O. Pathogenic mechanisms underlying idiopathic pulmonary fibrosis. Annu. Rev. Pathol. 2022;17:515–546. doi: 10.1146/annurev-pathol-042320-030240. [DOI] [PubMed] [Google Scholar]
  • 25.Larson-Casey J.L., He C., Carter A.B. Mitochondrial quality control in pulmonary fibrosis. Redox Biol. 2020;33 doi: 10.1016/j.redox.2020.101426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Popov L.D. Mitochondrial biogenesis: an update. J. Cell Mol. Med. 2020;24:4892–4899. doi: 10.1111/jcmm.15194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Bueno M., Calyeca J., Rojas M., Mora A.L. Mitochondria dysfunction and metabolic reprogramming as drivers of idiopathic pulmonary fibrosis. Redox Biol. 2020;33 doi: 10.1016/j.redox.2020.101509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Zhong W.J., Yang H.H., Guan X.X., Xiong J.B., Sun C.C., Zhang C.Y., Luo X.Q., Zhang Y.F., Zhang J., Duan J.X., Zhou Y., Guan C.X. Inhibition of glycolysis alleviates lipopolysaccharide-induced acute lung injury in a mouse model. J. Cell. Physiol. 2019;234:4641–4654. doi: 10.1002/jcp.27261. [DOI] [PubMed] [Google Scholar]
  • 29.Yang H.H., Duan J.X., Liu S.K., Xiong J.B., Guan X.X., Zhong W.J., Sun C.C., Zhang C.Y., Luo X.Q., Zhang Y.F., Chen P., Hammock B.D., Hwang S.H., Jiang J.X., Zhou Y., Guan C.X. A COX-2/sEH dual inhibitor PTUPB alleviates lipopolysaccharide-induced acute lung injury in mice by inhibiting NLRP3 inflammasome activation. Theranostics. 2020;10:4749–4761. doi: 10.7150/thno.43108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Tao J.H., Liu T., Zhang C.Y., Zu C., Yang H.H., Liu Y.B., Yang J.T., Zhou Y., Guan C.X. Epoxyeicosatrienoic acids inhibit the activation of murine fibroblasts by blocking the TGF-beta1-smad2/3 signaling in a PPARgamma-dependent manner. Oxid. Med. Cell. Longev. 2022;2022 doi: 10.1155/2022/7265486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Zhong W.J., Liu T., Yang H.H., Duan J.X., Yang J.T., Guan X.X., Xiong J.B., Zhang Y.F., Zhang C.Y., Zhou Y., Guan C.X. TREM-1 governs NLRP3 inflammasome activation of macrophages by firing up glycolysis in acute lung injury. Int. J. Biol. Sci. 2023;19:242–257. doi: 10.7150/ijbs.77304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Jiang H.L., Yang H.H., Liu Y.B., Zhang C.Y., Zhong W.J., Guan X.X., Jin L., Hong J.R., Yang J.T., Tan X.H., Li Q., Zhou Y., Guan C.X. L-OPA1 deficiency aggravates necroptosis of alveolar epithelial cells through impairing mitochondrial function during acute lung injury in mice. J. Cell. Physiol. 2022;237:3030–3043. doi: 10.1002/jcp.30766. [DOI] [PubMed] [Google Scholar]
  • 33.Martínez-Reyes I., Chandel N.S. Mitochondrial TCA cycle metabolites control physiology and disease. Nat. Commun. 2020;11:102. doi: 10.1038/s41467-019-13668-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Cheng D., Xu Q., Wang Y., Li G., Sun W., Ma D., Zhou S., Liu Y., Han L., Ni C. Metformin attenuates silica-induced pulmonary fibrosis via AMPK signaling. J. Transl. Med. 2021;19:349. doi: 10.1186/s12967-021-03036-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Cui H., Xie N., Banerjee S., Dey T., Liu R.M., Antony V.B., Sanders Y.Y., Adams T.S., Gomez J.L., Thannickal V.J., Kaminski N., Liu G. CD38 mediates lung fibrosis by promoting alveolar epithelial cell aging. Am. J. Respir. Crit. Care Med. 2022;206:459–475. doi: 10.1164/rccm.202109-2151OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Li Z., Zhang H. Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression. Cell. Mol. Life Sci. 2016;73:377–392. doi: 10.1007/s00018-015-2070-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Vaupel P., Multhoff G. Revisiting the Warburg effect: historical dogma versus current understanding. J. Physiol. 2021;599:1745–1757. doi: 10.1113/JP278810. [DOI] [PubMed] [Google Scholar]
  • 38.Zhu W., Chen X., Guo X., Liu H., Ma R., Wang Y., Liang Y., Sun Y., Wang M., Zhao R., Gao P. Low glucose-induced overexpression of HOXC-AS3 promotes metabolic reprogramming of breast cancer. Cancer Res. 2022;82:805–818. doi: 10.1158/0008-5472.Can-21-1179. [DOI] [PubMed] [Google Scholar]
  • 39.Hu B., Yu M., Ma X., Sun J., Liu C., Wang C., Wu S., Fu P., Yang Z., He Y., Zhu Y., Huang C., Yang X., Shi Y., Qiu S., Sun H., Zhu A.X., Zhou J., Xu Y., Zhu D., Fan J. IFNalpha potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment. Cancer Discov. 2022;12:1718–1741. doi: 10.1158/2159-8290.CD-21-1022. [DOI] [PubMed] [Google Scholar]
  • 40.Han R., Liang J., Zhou B. Glucose metabolic dysfunction in neurodegenerative diseases-new mechanistic insights and the potential of hypoxia as a prospective therapy targeting metabolic reprogramming. Int. J. Mol. Sci. 2021;22 doi: 10.3390/ijms22115887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Fan Z., Li L., Li X., Zhang M., Dou M., Zhao J., Cao J., Deng X., Zhang M., Li H., Suo Z. Anti-senescence role of heterozygous fumarate hydratase gene knockout in rat lung fibroblasts in vitro. Aging (Albany NY) 2019;11:573–589. doi: 10.18632/aging.101761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Lussey-Lepoutre C., Hollinshead K.E., Ludwig C., Menara M., Morin A., Castro-Vega L.J., Parker S.J., Janin M., Martinelli C., Ottolenghi C., Metallo C., Gimenez-Roqueplo A.P., Favier J., Tennant D.A. Loss of succinate dehydrogenase activity results in dependency on pyruvate carboxylation for cellular anabolism. Nat. Commun. 2015;6:8784. doi: 10.1038/ncomms9784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Doan M.T., Teitell M.A. Krebs and an alternative TCA cycle. Cell Res. 2022;32:509–510. doi: 10.1038/s41422-022-00664-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Kumar A., Abdelmalak B., Inoue Y., Culver D.A. Pulmonary alveolar proteinosis in adults: pathophysiology and clinical approach. Lancet Respir. Med. 2018;6:554–565. doi: 10.1016/S2213-2600(18)30043-2. [DOI] [PubMed] [Google Scholar]
  • 45.Eldeeb M.A., Thomas R.A., Ragheb M.A., Fallahi A., Fon E.A. Mitochondrial quality control in health and in Parkinson's disease. Physiol. Rev. 2022;102:1721–1755. doi: 10.1152/physrev.00041.2021. [DOI] [PubMed] [Google Scholar]
  • 46.Bennett C.F., Latorre-Muro P., Puigserver P. Mechanisms of mitochondrial respiratory adaptation. Nat. Rev. Mol. Cell Biol. 2022;23:817–835. doi: 10.1038/s41580-022-00506-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Zhao M., Wang Y., Li L., Liu S., Wang C., Yuan Y., Yang G., Chen Y., Cheng J., Lu Y., Liu J. Mitochondrial ROS promote mitochondrial dysfunction and inflammation in ischemic acute kidney injury by disrupting TFAM-mediated mtDNA maintenance. Theranostics. 2021;11:1845–1863. doi: 10.7150/thno.50905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Hwang J.H., Kim K.M., Oh H.T., Yoo G.D., Jeong M.G., Lee H., Park J., Jeong K., Kim Y.K., Ko Y.G., Hwang E.S., Hong J.H. TAZ links exercise to mitochondrial biogenesis via mitochondrial transcription factor A. Nat. Commun. 2022;13:653. doi: 10.1038/s41467-022-28247-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Lefranc C., Friederich-Persson M., Foufelle F., Nguyen Dinh Cat A., Jaisser F. Adipocyte-mineralocorticoid receptor alters mitochondrial quality control leading to mitochondrial dysfunction and senescence of visceral adipose tissue. Int. J. Mol. Sci. 2021;22 doi: 10.3390/ijms22062881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Salazar G., Cullen A., Huang J., Zhao Y., Serino A., Hilenski L., Patrushev N., Forouzandeh F., Hwang H.S. SQSTM1/p62 and PPARGC1A/PGC-1alpha at the interface of autophagy and vascular senescence. Autophagy. 2020;16:1092–1110. doi: 10.1080/15548627.2019.1659612. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Multimedia component 1
mmc1.pptx (22.6MB, pptx)

Data Availability Statement

Data will be made available on request.


Articles from Heliyon are provided here courtesy of Elsevier

RESOURCES